Home
MosaiQMedia
MosaiQ
-
Unlock Lab Efficiencies with an AliveDx Evaluation
The global IVD market portfolio and associated technologies are constantly evolving. AliveDx utilizes innovative technology that provides more automation and multiplex testing to drive lab workflow efficiency. Our MosaiQ® and LumiQ® solutions are designed to help transform autoimmune and allergy
-
Multiplexing: Streamline Autoimmune Testing with MosaiQ AiPlex® CTDplus
In the world of autoimmune diagnostics, time and accuracy are everything. Traditional serological testing often involves multiple assays, manual steps, and long turnaround times. AliveDx is changing that with the MosaiQ® AiPlex CTDplus, a fully automated multiplex microarray immunoassay designed
-
How Machine Learning Is Transforming CTD Diagnosis
In-vitro diagnostics (IVD) is entering a new era, one where artificial intelligence (AI) and multiplexed immunoassays converge to deliver fast, smart and accurate results. At AliveDx, we’re proud to be at the forefront of this transformation with our MosaiQ® and
-
Transforming Vasculitis Diagnostics: Multiplex Microarray Solutions for PR3, MPO & GBM Autoantibodies
In–vitro diagnostics (IVD) is undergoing a transformation, driven by automation and a syndromic approach enabled by multiplexing technologies. At AliveDx, we’re proud to lead this evolution with the MosaiQ AiPlex® VAS microarray, a fully automated multiplex immunoassay designed to detect
-
Machine learning classification based on a 15-autoantibody profile by a fully automated multiplex microarray immunoassay for autoimmune CTD diagnosis
Extended serological profiling may improve autoimmuneconnective tissue diseases (CTD) diagnosis.
-
MosaiQ® System Demonstration
Discover MosaiQ: A groundbreaking IVD solution for autoimmune diseases, allergy, and beyond.
